bobbybobby
MarketsStocksJoin Us

Precigen, Inc. Common Stock

PGEN

$7.74

-9.37%

Bobby Quantitative Model
Oct 5, 2026

PGEN

Precigen, Inc. Common Stock

$7.74

-9.37%
Oct 5, 2026
Bobby Quantitative Model

People also watch

버텍스 파마슈티컬

버텍스 파마슈티컬

VRTX

Analysis
모더나

모더나

MRNA

Analysis
리제네론 파마슈티컬스

리제네론 파마슈티컬스

REGN

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNY

Analysis

PGEN price trend

Historical Price
Current Price $7.74
Average Target $7.74
High Target $8.90
Low Target $6.58

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Precigen, Inc. Common Stock's 12-month outlook, with a consensus price target around $13.65 and implied upside of +76.4% versus the current price.

Average Target

$13.65

0 analysts

Implied Upside

+76.4%

vs. current price

Analyst Count

—

covering this stock

Price Range

$11 - $18

Analyst target range

Drowning in data?

Find the real signal!

Drowning in data?

Find the real signal!

PGEN Technical Analysis

Beta

0.92

0.92x market volatility

Max Drawdown

-40.5%

Largest decline past year

52-Week Range

$3-$9

Price range past year

Annual Return

+138.2%

Cumulative gain past year

PeriodPGEN ReturnS&P 500
1m+9.0%+0.6%
3m+40.5%+3.6%
6m+87.9%+14.6%
1y+138.2%+15.8%
ytd+80.8%+13.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

PGEN Fundamental Analysis

Quarterly Revenue

$54978000.0B

2026-06

Revenue YoY Growth

N/A

YoY Comparison

Gross Margin

94.9%

Latest Quarter

Free Cash Flow

$-115826000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Product
Service

Open an Account, get $2 TSLA now!

Open an Account, get $2 TSLA now!

Valuation Analysis: Is PGEN Overvalued?

PE

-3.0x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

-5.5x

Enterprise Value Multiple

People also watch

버텍스 파마슈티컬

버텍스 파마슈티컬

VRTX

Analysis
모더나

모더나

MRNA

Analysis
리제네론 파마슈티컬스

리제네론 파마슈티컬스

REGN

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis
Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNY

Analysis
Bobby
cs@bobby.ai

Product

  • Bobby AI

Partner

  • RockFlow Platform

Markets

  • Stock Event
  • Macro Event
  • Industry Event

Stocks

  • NVDA
  • AAPL
  • MSFT
  • AMZN
  • GOOG
  • META
  • TSLA
Privacy PolicyTerms of Use

© 2026 FLOW AI PTE. LTD. All Rights Reserved.

Bobby, the world's first financial AI Agent, is developed by Flow AI, an AI-driven company. Flow AI is dedicated to providing global investors with AI-powered financial services across multiple markets.

Waffo.com Limited (authorised distributor): RM 1903, 19/F Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.